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Abstract
Recent studies of inherited neurodegenerative disorders have suggested a linkage between the
propensity toward aggregation of mutant protein and disease onset. This is particularly apparent
for polyglutamine (polyQ) diseases caused by expansion of CAG-trinucleotide repeats. However,
a quantitative framework for relating aggregation kinetics with molecular mechanisms of
neurodegeneration initiation is lacking. Here, using the repeat-length-dependent age-of-onset in
polyQ diseases, we derived a mathematical model based on nucleation of aggregation kinetics to
describe genotype-phenotype correlations, and validated the model using both in vitro data and
clinical data. Instead of describing polyQ aggregation kinetics with a derivative equation, our model
divided age-of-onset (equivalent to the time required for aggregation) into two processes:
nucleation lag time (a first-order exponential function of CAG-repeat length) and elongation time.
With the exception of spinocerebellar ataxia (SCA) 3, the relation between CAG-repeat length and
age-of-onset in all examined polyQ diseases, including Huntington's disease, dentatorubral-
pallidoluysian atrophy and SCA1, -2, -6 and -7, could be well explained by three parameters derived
from linear regression analysis based on the nucleated growth polymerization model. These
parameters composed of probability of nucleation at an individual repeat, a protein concentration
associated factor, and elongation time predict the overall features of neurodegeneration initiation,
including constant risk for cell death, toxic polyQ species, main pathological subcellular site and the
contribution of cellular factors. Our model also presents an alternative therapeutic strategy
according to the distinct subcellular loci by the finding that nuclear localization of soluble mutant
protein monomers itself has great impact on disease onset.
Background
Accumulation of misfolded proteins into protein aggre-
gates is a hallmark of various aging-associated neurode-
generative diseases, including Alzheimer's, Parkinson's
and polyglutamine (polyQ) diseases [1,2]. The biochemi-
cal properties of the affected proteins dictate their propen-
sity to aggregate as well as the age-of-onset of these
diseases. To date, nine inherited neurodegenerative disor-
ders known as polyQ disease have been identified, includ-
ing Huntington's disease (HD), spinal and bulbar
muscular atrophy (SBMA), dentatorubral-pallidoluysian
atrophy (DRPLA) and spinocerebellar ataxia (SCA) 1–3, -
6, -7 and -17 [3]. These diseases have little in common at
the genetic level other than the presence of polyQ
sequence. However, there is a strong and consistent
inverse relation between the length of the expansion and
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the age-of-onset in these disorders [3,4]. Despite the fact
that an understanding of genotype-phenotype relation-
ships might offer insights into the intrinsic toxicity of
polyQ peptides and the contribution of tissue context fac-
tors, such correlational analyses have rarely been
attempted for the various polyQ diseases [4-6]. Those
studies that have been performed have provided limited
information because the parameters derived from a sim-
ple exponential regression analysis are highly variable.
Rather than providing evidence that the genotype-pheno-
type relationship is modified by the nature of the protein
encoded by each disease gene, this variability suggests
deficiencies in the basic model describing the relation-
ship.
Another common feature of polyQ diseases is the neuro-
nal accumulation of the mutant protein in nuclear or cyto-
plasmic inclusion [2,7]. In addition to the length
dependence of disease onset, the length of polyQ
sequence also predicted the propensity toward aggrega-
tion of polyQ-containing peptides [8,9]. The aggregation
of polyQ peptides in vitro follows a simple nucleated
growth polymerization pathway, implying crystallization
or, in some cases, amyloid fibril formation [9,10]. Nucle-
ated growth polymerization is a two-stage process consist-
ing of the energetically unfavorable formation of a
nucleus (i.e., nucleation), followed by efficient elongation
of the nucleus via sequential additions of monomers [10].
Its kinetics is exemplified by long lag time followed by
rapid aggregate growth, with a strong dependence of
aggregation lag time on monomer concentration [10].
Nucleated growth polymerization has been proposed to
govern disease progression kinetics in Alzheimer's and
prion-related diseases [11]. We and others have previously
suggested a linkage between the biophysics of polyQ
aggregation nucleation and HD onset [9,12]. The actual
mechanism of the generation of nuclei based on polyQ
sequences will be structurally complex, but a kinetic
parameter of nucleation is expected to be an exponential
function of repeat length [13]. The polyQ length depend-
ence of disease onset correlates strongly with the tendency
of expanded polyQ proteins to aggregate in disease mod-
els [14,15]. Accordingly, we have focused on this length
dependence of age-of-onset and nucleation kinetics to
derive a stochastic mathematical model describing geno-
type-phenotype correlations in polyQ diseases.
Accumulating evidence strongly suggests that the cell
nucleus is the main pathological subcellular site for SCA1,
-7 and HD [16-18], whereas the cytoplasm is thought to
be the site for SCA2 and SCA6 [19,20]. Our mathematical
model clearly subdivided polyQ diseases into two groups
in accordance with the presumed main pathological sub-
cellular site. From a comparison of the parameters based
on the nucleated growth polymerization model, our
present study leads us to propose alternative therapeutic
targets according to the distinct subcellular loci.
Methods
Data collection
Clinical data from affected patients with a mutation in the
responsible gene were obtained from previous studies
[5,6,21-37]. Patients with a homozygous mutation were
excluded. An insufficient number of patients with SBMA
and SCA17 were available, so these diseases were not
included in the analysis. A total of 1398 patients were ana-
lyzed: 221 with SCA1, 141 with SCA2, 308 with SCA3,
132 with SCA6, 188 with SCA7, 317 with HD and 91 with
DRPLA.
Modeling
The derivation of equation describing polyQ peptide
aggregation kinetics in a nucleated growth polymerization
mechanism has been described by Chen et al. [9] as fol-
lows:
where Δ is the concentration of monomer that has been
incorporated into polymers, k+ is the forward elongation
rate constant, kn* is the equilibrium constant describing
the monomer-nucleus equilibrium, c is the bulk concen-
tration of monomers, n* is the critical nucleus, and t is
time. This equation represents the overall pathway of
nucleated growth polymerization. Further, kinetic studies
also suggest that, in this mathematical model, the only
factor related to CAG-repeat length is the nucleation con-
stant, kn*[9,38,39]. However, nucleation kinetics cannot
be determined directly through physical measurement of
nuclei because nucleation is a very rare event and nuclei,
once formed, quickly either collapse to bulk phase mono-
mer or proceed along the productive aggregation path-
way. Aggregation occurs with a lag phase and a growth
phase that reflect an underlying nucleation-polymeriza-
tion mechanism. The lag time of aggregation (aggregation
lag time) as a kinetic parameter of nucleation was calcu-
lated by extrapolation of the linear region of the growth
phase to the base line of the lag phase by experimental
observation using Equation 1 (Figure 1A). However,
polyQ aggregation kinetics also feature lag phases that can
be abbreviated by seeding [8,40]. Instead of using polyQ
aggregation kinetics to describe the overall pathway of
nucleated growth polymerization, we hypothesized a
mathematical model that divides the time required for
aggregation into two processes: CAG-repeat-length-
dependent nucleation lag time, and repeat-length-inde-
pendent elongation time from elongation kinetics using
aggregates of the polyQ peptides as a seed [8,38,39]. In
this mathematical model, nucleation lag time (a proxy for
aggregation lag time) is determined by the time required
D= +
+ 12
22 2 / *
(* ) kk c t n
n (1)Molecular Neurodegeneration 2009, 4:29 http://www.molecularneurodegeneration.com/content/4/1/29
Page 3 of 12
(page number not for citation purposes)
for aggregation and elongation time, as a function of
repeat length.
In the nucleated growth polymerization pathway, aggre-
gate growth is exponential. A previous study that
employed a mutagenic analysis to the nucleation propen-
sity of Alzheimer's β-amyloid showed that nucleation lag
time of mutant β-amyloid could be related directly to the
rate of aggregate growth [41]. Aggregate growth is largely
dependent on nucleation lag time. In polyQ diseases, by
contrast, the relationship between age-of-onset and the
number of repeats is typically characterized by an expo-
nential curve in which the change in the age-of-onset as a
result of additional inherited repeats decreases with the
number of repeats [4]. Moreover, as noted by Clarke et al.,
in clinically affected HD patients there is a first-order
exponential decline in the number of surviving caudate
nucleus neurons with time (based on metabolic activity),
regardless of CAG-repeat length [42]. These findings,
taken together with the linkage between aggregation
nucleation of polyQ peptides and HD age-of-onset [9,12],
suggest that the nucleation lag time for polyQ aggregation
could be represented by a first-order exponential function
of CAG-repeat lengths. In vitro studies also showed that
the elongation rates of polyQ peptides changed little as a
function of repeat-length [8,38,39]. Assuming such an
identity in the elongation rate constant, and given the fact
that the aggregation rate is t2 dependent [9,39], the age-of-
onset in polyQ diseases could be represented as a function
of CAG-repeat lengths as follows:
where tA is age-of-onset of the disease (equivalent to the
time required for aggregation), tE is elongation time, tN is
nucleation lag time and x is the repeat-length number.
The identical relationship between nucleation lag time
and CAG-repeat length was also proposed by Perutz et al.
based on chemicalthermodynamics [13]. According to the
theory of nucleation of aggregates, the probability of
nucleation would be an exponential function of the free
energy of formation of the nucleus, and is proportional to
exp [-ΔGcrit/kT] [13]. ΔGcrit  is the critical free energy
required to create a spherical nucleus, k is Boltzmann's
constant, and T is absolute temperature. Since the addi-
tion of each glutamine stabilizes the helix structure by the
()
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Validity of the model using in vitro data and clinical data Figure 1
Validity of the model using in vitro data and clinical data. (A) The model was validated using in vitro data. It is impossible 
to experimentally determine the aggregation kinetics for polyQ peptides at physiological concentrations. However, assuming 
no change in mechanism, Chen et al, calculated the aggregation kinetics at low concentration (0.1 nM) from data obtained from 
aggregation of polyQ peptides at high concentration using the kinetics parameters of Equation 1 [9]. We tested the linear cor-
relation of the natural log transform of these data, which represents the time required for 0.9% aggregation of polyQ peptides, 
against the polyQ tract number. A simple logarithmic transformation of the aggregation lag times did not show a linear rela-
tionship. In contrast, using tE
2 = 27 in our model, nucleation lag times perfectly matched a linear relation. (B) A linear regres-
sion analysis of natural log-transformed age-of-onset versus CAG size in SCA1 patients revealed that the plots of residual error 
versus CAG size were better fit to a U-shaped curve.
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formation of another three or four hydrogen bonds [43],
alternation of free energy by the addition of each repeat to
be expected constant. Therefore, probability of nucleation
is likely to rise exponentially with the number of repeats.
Pn+1/Pn = exp [ΔG+1/kT], where Pn+1 is the probability of
nucleation at repeat number n + 1, Pn is the probability of
nucleation at repeat number n, ΔG+1 is the change of free
energy by one additional repeat. Nucleation lag time is
defined as that lag time which is required for the forma-
tion of a critical number of stable nuclei leading to polym-
erization. In vitro aggregation kinetics of polyQ peptide
also showed that the critical nucleus – the number of
monomeric units comprising the nucleus – is equal to 1
[9]. Thus, under the condition of monomeric nucleus,
nucleation lag time could be represented by an exponen-
tial function of repeat length as follows:
where  Ncri  is a critical number of nucleus leading to
polymerization at a given space, NA is Avogadro's number,
Cmo is the bulk concentration of mutant protein mono-
mers, R0 is the rate of formation of stable nuclei at the first
structure, m is the number of repeat length at the first
structure stable enough to form a nucleus, and eb is the
probability of nucleation at an individual repeat.
Statistical analysis
For statistical analysis, we used the UNISTAT 5.6 statistical
package for Windows (Unistat). To examine the associa-
tion between age-of-onset and CAG size, we used linear
regression with logarithmic transformation, allowing an
exponential function to be treated as an intrinsically lin-
ear model as follows:
where In(a) is the intercept, b is the slope, and ε represents
the residual error. Of course, the slope factor represents
the probability of nucleation at an individual repeat and
is determined by a nucleation constant, kn*, because kn* =
c*/cn* (c* is the concentration of nuclei, c is the bulk con-
centration of monomers, n* is the critical nucleus) [10].
The intercept is composed of the complex factors (Equa-
tion 3). However, it is expected that its variation is mainly
dependent on the concentration of soluble mutant pro-
tein monomers. A linear regression analysis was then
applied to determine tE
2 for the best fit to a linear relation-
ship between the logarithm of tN and CAG size. This was
achieved by comparing the R2 for a quadratic curve and a
linear model. Then, to confirm that our mathematical
model is a significantly better fit than a simple exponen-
tial regression model, we compared the R2 values for lin-
ear regression analyses derived from simple natural log-
transformed age-of-onset data without tE
2. We used the
residual error as another measure of goodness-of-fit. The
small number of individuals with shortest and longest
CAG-repeat sizes precluded a rigorous statistical analysis
of these groups because they would have overruled the
bulk of the other data and thus had too great an impact on
the model. Applying this procedure, 94% to 98% of
patients in each disease category were included in the
analysis.
Results
Validated the model using in vitro data
In previous study, using the in vitro aggregation lag time of
a series of polyQ peptides as a function of CAG size,
described by Chen et al. [9], we compared the relationship
between median age-at-onset of HD and particular repeat
sizes, demonstrating a significant linear correlation [12].
Instead of using polyQ peptide aggregation kinetics to
describe the overall pathway of nucleated growth polym-
erization [9], we successfully developed a mathematical
model that divided the time required for aggregation (tA)
into two processes governed by nucleation lag time (tN), a
first-order exponential function of CAG size, and elonga-
tion time (tE), to yield the following relationship: (tA
2 -
tE
2)1/2 = tN = ae-bx(see Methods). Then, we tested the linear
correlation with logarithmic transformation, allowing an
exponential function to be treated as an intrinsically lin-
ear model. A simple logarithmic transformation of the in
vitro aggregation lag times against the polyQ tract number
did not show a linear relationship (data not shown).
These data represents the time required for 0.9% aggrega-
tion of polyQ peptides [9]. In contrast, when tE
2 = 27, the
application of our model to in vitro nucleation lag times
versus CAG size yields a plot that is perfectly fit with an
exponential function (Figure 1A).
Validated the model using clinical data
Based on the nucleated growth polymerization model of
polyQ peptides aggregation, we used the model for
describing the relationship between CAG-repeat length
and age-of-onset in polyQ diseases as follows: In(tA
2 -
tE
2)1/2 = In(a) - bx + ε (see Methods), where tA is age-of-
onset of the disease (equivalent to the time required for
aggregation), ε represents the residual error and x is the
repeat-length number. We subsequently validated the
model using available clinical data from patients with
HD, DRPLA and SCA1–3, -6 and -7 [5,6,21-37]. A recent
study of the relationship between age-of-onset in HD and
CAG size in the HD gene has shown that a two-segment
exponential regression curve provides a significantly bet-
ter fit than a simple exponential regression model [44]. A
similar tendency was also observed for SCA1, -2, -6, and -
7. In fact, in these disorders, a linear regression analysis of
natural log-transformed age-of-onset versus CAG size
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revealed that plots of residual error versus CAG size were
consistently better fit to a U-shaped curve (Figure 1B).
These findings strongly support our model, since a regres-
sion analysis of natural log-transformed age-of-onset, tA =
(tN
2 + tE
2)1/2, versus CAG size is better fit to a U-shaped
curve than a simple linear model, except for the case
where elongation time is 0 (tE = 0). Therefore, elongation
time is determined for each polyQ disease by identifying
when the coefficients of determination (R2) for a quad-
ratic curve and a linear model are identical (Figures 2, 3
and 4). This procedure restores the uncorrelation of the
residual error, and consistently obtained higher R2 values
than linear regression analyses derived from simple natu-
ral log-transformed age-of-onset data without tE
2 in dem-
onstrating a significant better fit than a simple
exponential regression model (Table 1). We also analyzed
the relationship using a logarithmic transformation of (tA
- t) against CAG size, corresponding to an off-pathway of
nucleated growth polymerization. Then, t is determined
for each polyQ disease by identifying when the R2 for a
quadratic curve and linear model are identical (data not
shown). However, a higher R2  value was consistently
obtained with (tA
2 - tE
2)1/2 versus CAG size, indicating an
on-pathway of nucleated growth polymerization.
In contrast to the linear regression analysis of genotype-
phenotype correlation in other polyQ diseases we exam-
ined, SCA3 clearly did not conform to the nucleated
growth polymerization model. A natural log-transformed
age-of-onset in a total of 308 SCA3 patients versus CAG
size in the ataxin-3 gene was the best fit to a negative
quadratic function (Figure 5). This suggests that, despite
shared pathological findings, including nuclear inclusion,
a different mechanism underlies SCA3 pathogenesis.
The validity of the model is also supported by clinical data
on disease progression. A statistical analysis of the
detailed information provided by activity of daily living
(ADL) milestones in SBMA patients and their relationship
to the CAG-repeat length of the androgen receptor gene
has demonstrated that the ADL milestone is significantly
related to CAG size [45]. In contrast, the rate of disease
progression showed no significant correlation to CAG size
[45]. A similar lack of correlation between the rate of dis-
ease progression and CAG size was observed for HD
patients [46]. Interestingly, the slopes of the regression
curves for age-at-onset of each ADL milestone versus CAG
size likely parallel one another [45], suggesting that the
repeat-length-dependent parameter is conserved with
respect to disease progression. In our model, the slope (b)
factor is only dependent on CAG-repeat length, which is
determined by a nucleation constant, kn* (see Methods).
Therefore, the constancy of the slope could account for
the fact that CAG-repeat length has little effect on the rate
of disease progression, but is related to age-at-onset for
each ADL milestone. In fact, the relationship between the
age-at-onset of each ADL milestone in SBMA patients and
CAG-repeat length also conformed to the nucleated
growth polymerization model (data not shown).
Linear regression analysis of HD, DRPLA, SCA1, -2, -6 and 
-7 based on the model
HD: A total of 317 HD patients with expanded CAG
repeats in the huntingtin gene was analyzed. A regression
analysis of natural log-transformed (tA
2 -  tE
2)1/2 against
CAG size provided the best fit to a linear model (-0.0662x
+ 6.657) when tE
2 = 215 (Figure 2A). DRPLA: A total of 91
DRPLA patients with expanded CAG repeats in the
atrophin-1 gene was analyzed. A regression analysis of
natural log-transformed (tA
2 - tE
2)1/2 against CAG size pro-
vided the best fit to a linear model (-0.1247x + 11.011)
when  tE
2 = 0 (Figure 2B). SCA1: A total of 221 SCA1
patients with expanded CAG repeats in the ataxin-1 gene
was analyzed. A regression analysis of natural log-trans-
formed (tA
2 - tE
2)1/2 against CAG size provided the best fit
to a linear model (-0.0569x + 6.249) when tE
2 = 170 (Fig-
ure 3A). SCA2: A total of 141 SCA2 patients with
expanded CAG repeats in the ataxin-2 gene was analyzed.
Table 1: Parameters based on the model: In (tA
2 - tE
2)1/2 = In(a) - bx + ε
HD SCA1 SCA7 DRPLA SCA2 SCA6
% patients 98.42 97.74 97.87 96.70 98.58 93.94
tE
2 215 170 30 0 80 700
intercept (In(α)) 6.657 6.249 6.513 11.011 8.377 9.553
± SE 0.1432 0.1516 0.1697 0.7543 0.3160 0.4076
slope (-b) 0.0662 0.0569 0.0658 0.1247 0.1217 0.2567
± SE 0.00316 0.00298 0.00338 0.0116 0.00773 0.0181
F test 437.65 364.59 380.43 114.96 248.33 201.92
(P) 3.23E-61 4.13E-48 1.84E-46 1.58E-17 1.45E-32 1.23E-27
R2 0.5854 0.6301 0.6764 0.5721 0.6445 0.6234
R2 * 0.5321 0.6259 0.6595 0.5721 0.6391 0.6012
% patients = percent of patients comprised the model, SE = standard error, R2 = coefficient determination, R2 * = R2 derived from linear regression 
analysis of simple logarithmic transformation of age-of-onset without tE
2.Molecular Neurodegeneration 2009, 4:29 http://www.molecularneurodegeneration.com/content/4/1/29
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A regression analysis of natural log-transformed (tA
2 -
tE
2)1/2 against CAG size provided the best fit to a linear
model (-0.1217x  + 8.377) when tE
2 = 80 (Figure 3B).
SCA6: A total of 132 SCA6 patients with expanded CAG
repeats in the alpha-1A-calcium channel gene was ana-
lyzed. A regression analysis of natural log-transformed
(tA
2 - tE
2)1/2 against CAG size provided the best fit to a lin-
ear model (-0.2567x + 9.553) when tE
2 = 700 (Figure 4A).
SCA7: A total of 188 SCA7 patients with expanded CAG
repeats in the ataxin-7 gene was analyzed. A regression
analysis of natural log-transformed (tA
2 -  tE
2)1/2 against
CAG size provided the best fit to a linear model (-0.0658x
+ 6.513) when tE
2 = 30 (Figure 4B).
Parameters derived from linear regression analysis
Three parameters, represented by the slope and intercept
of the natural log-transformed linear regression curve, and
elongation time, as well as descriptive statistics for each
disease are summarized in Table 1. From Equations 3 (see
Methods), the slope factor of the regression curve, eb, rep-
resents the probability of nucleation at an individual
repeat (governed by the nucleation constant, kn*), and the
intercept (In(a)) is interpreted as a variable that is
inversely related to the concentration of soluble mutant
protein monomers.
In genotype-phenotype correlations, each polyQ disease
shows a characteristic threshold of CAG-repeat length
[3,4]. SCA6 arises from a relatively small expansion with
as few as 21 repeats. This contrasts with SCA1, -2, -7 and
HD, where 35–40 repeats cause disease, and DRPLA,
which arises from an even larger expansion (> 50 repeats).
Three parameters derived from statistical analysis can well
explain the relationship between CAG-repeat length and
age-of-onset in any of these disorders. For example, these
parameters indicate that a relatively large expansion
required for disease onset in DRPLA is mainly due to the
lower concentration of soluble mutant protein monomers
(Figure 2B). In addition, a comparison of these parame-
ters should reveal which factors strongly influence disease
onset. In polyQ diseases, symptoms typically appear in
adulthood; in DRPLA, infant-onset of the disease is occa-
Linear regression analysis of HD and DRPLA based on the model Figure 2
Linear regression analysis of HD and DRPLA based on the model. (A) A total of 317 HD patients with expanded 
CAG repeats in the huntingtin gene was analyzed. Inspection of logarithmically transformed mean age-at-onset versus CAG 
size plots identified 75 and 121 CAG as relative outliers. These data were therefore excluded from further study. A regression 
analysis of natural log-transformed (tA
2 - tE
2)1/2 against CAG size provided the best fit to a linear model (-0.0662x + 6.657) when 
tE
2 = 215. (B) A total of 91 DRPLA patients with expanded CAG repeats in the atrophin-1 gene was analyzed. Inspection of log-
arithmically transformed mean age-at-onset versus CAG size plots identified 69 and 79 CAG repeats as relative outliers. These 
data were excluded from further study. A regression analysis of natural log-transformed (tA
2 - tE
2)1/2 against CAG size provided 
the best fit to a linear model (-0.1247x + 11.011) when tE
2 = 0.
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sionally seen, but this is never the case for SCA6. Our
model clearly pointed to elongation time as a contributor
to infant-onset, while adult-onset was mostly attributable
to the nucleation lag time (Table 1).
Variance in nucleation lag times
It is now believed that the identification of non-CAG size-
dependent factors that explain residual onset age variance
would possibly allow treatments that retard disease onset
of polyQ disease. Regression analysis of HD, DRPLA and
SCA1, -2, -6, and -7 showed that 57 to 68% variance of
nucleation lag times is explained by the number of repeat
units on the mutant allele (Table 1). However, using
median nucleation lag time with a particular repeat size,
there was a high significant correlation (R = 0.96 ~ 0.99)
between CAG size and median nucleation lag times (data
not shown), implying that the residual variance in nucle-
ation lag times is mainly due to the variance at a particular
repeat size. Our mathematical model (Equation 3) sug-
gests that the concentration of soluble mutant protein
monomers accounts for a major contributor to the resid-
ual variance in age-of-onset. Importantly, nucleation is a
very rare event [13]. Therefore, only a small difference in
concentration of soluble mutant protein monomers could
result in a large difference in nucleation lag times, which
directly reflects to onset age variance. In addition to the
expression levels of a gene, the complexity of the cellular
environment, including degradation and transport proc-
esses capable of partitioning proteins into different
molecular forms and compartments, and the presence of
chaperones will contribute to the differences in intracellu-
lar concentration of mutant protein.
Discussion
Three parameters derived from linear regression analysis
based on the nucleated growth polymerization model
predict the overall features of neurodegeneration initia-
tion of polyQ diseases, including toxic polyQ species,
Linear regression analysis of SCA1 and -2 based on the model Figure 3
Linear regression analysis of SCA1 and -2 based on the model. (A) A total of 221 SCA1 patients with expanded CAG 
repeats in the ataxin-1 gene was analyzed. Inspection of logarithmically transformed mean age-at-onset versus CAG size plots 
identified 40, 69 and 81 CAG repeats as relative outliers. These data were therefore excluded from further analysis. Logarith-
mically transformed mean age-of-onset versus CAG size was the best fit to a quadratic curve. A regression analysis of natural 
log-transformed (tA
2 - tE
2)1/2 against CAG size provided the best fit to a linear model (-0.0569x + 6.249) when tE
2 = 170. (B) A 
total of 141 SCA2 patients with expanded CAG repeats in the ataxin-2 gene was analyzed. Inspection of logarithmically trans-
formed mean age-at-onset versus CAG size plots identified 51 and 57 CAG repeats as relative outliers. These data were 
excluded from further analysis. Logarithmically transformed mean age-of-onset versus CAG size was best fit to a quadratic 
curve. A regression analysis of natural log-transformed (tA
2 - tE
2)1/2 against CAG size provided the best fit to a linear model (-
0.1217x + 8.377) when tE
2 = 80.
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constant risk for cell death, main pathological subcellular
site and the contribution of cellular factors, and provide
an explanation for the aggregation of relatively short
expanded polyQ tracts in SCA6.
Unexpectedly, a linear regression analysis of each disease
showed that tE
2 varied from 0 to 700 (Table 1). This result,
which is in contrast to the findings of a previous study
[47], suggests that the specific oligomeric conformation of
expanded polyQ is not uniformly toxic to neuronal cells
in polyQ diseases. Instead, the validity of the nucleated
growth polymerization model in any of these diseases
indicates that toxic polyQ species accrues uniformly on-
pathway of nucleated growth polymerization. Even
though the disease-causing polyQ proteins are widely
expressed, specific collections of neurons are more suscep-
tible in each polyQ disease, resulting in characteristic pat-
terns of pathology and clinical symptoms. Recent studies
have suggested that altered protein function is fundamen-
tal to pathogenesis, with protein context of the expanded
polyQ having key roles in disease specific processes [48].
Therefore, varied tE suggest that a growth phase of aggrega-
tion may represent disease specific processes affected by
protein context of the expanded polyQ.
The clinical manifestations of inherited neurodegenera-
tive diseases are often delayed for periods from years to
decades. This observation has led to the idea that, in these
disorders, neurons die from cumulative damage. Consist-
ent with a cumulative damage model, a failure of protein
folding quality control has been proposed for the patho-
genesis of polyQ diseases [49,50]. A critical prediction of
the cumulative damage hypothesis is that the probability
of neuronal death increase over time (sigmoidal kinetics).
However, Clarke et al. demonstrated that, in many aging-
associated neurodegenerative diseases, including HD, the
kinetics of neuronal death appear to be exponential
[42,51]. Exponential kinetics, which also describe radio-
active decay, indicates that in the neurodegenerations, the
risk of cell death is constant (in some cases, as described
by Clarke et al., an exponentially decreasing risk of death)
over time. They accounted for this constancy by proposing
Linear regression analysis of SCA6 and -7 based on the model Figure 4
Linear regression analysis of SCA6 and -7 based on the model. (A) A total of 132 SCA6 patients with expanded CAG 
repeats in the alpha-1A-calcium channel gene was analyzed. Inspection of logarithmically transformed mean age-at-onset versus 
CAG size plots identified 27–29 CAG repeats as relative outliers and showed the best fit to a quadratic curve. A regression 
analysis of natural log-transformed (tA
2 - tE
2)1/2 against CAG size provided the best fit to a linear model (-0.2567x + 9.553) when 
tE
2 = 700. (B) A total of 188 SCA7 patients with expanded CAG repeats in the ataxin-7 gene was analyzed. Inspection of loga-
rithmically transformed mean age-at-onset versus CAG size plots identified 38 and 75 CAG repeats as relative outlier. These 
data were therefore excluded from further study. A regression analysis of natural log-transformed (tA
2 - tE
2)1/2 against CAG size 
provided the best fit to a linear model (-0.0658x + 6.513) when tE
2 = 30.
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a one-hit model in which the death of a neuron is initiated
randomly in time by a single, rare catastrophic event
rather than resulting from cumulative damage [42,51].
Thereafter, Perutz et al. proposed that nucleation is
responsible for this kind of rare event, based on the fact
that nucleation occurs randomly in time and space [13].
We have successfully established the common quantita-
tive connection among polyQ diseases between the nucle-
ation kinetics based on polyQ sequence and the repeat-
length-dependent age-of-onset, implicating nucleation of
protein aggregation kinetics as the basis for the genotype-
phenotype correlations. In our model, the slope of the
regression curve, which is a constant factor related only to
CAG-repeat length, represents the probability of nuclea-
tion at an individual repeat and is equivalent to the con-
stant risk of neuronal cells death at an individual repeat,
consistent with Perutz's hypothesis [13]. Remarkably,
nucleation and nucleation dependent polymerization
exhibits kinetics consistent with both a constant and an
exponentially decreasing risk of neuronal death in the
neurodegenerations. Taken together, these findings pro-
vide indirect evidence that the genetic gain-of-function
mechanism of polyQ pathogenesis is attributable to a crit-
ical nucleation event; thus, cytotoxicity accrues through
the process of nucleation and nucleation-dependent
polymerization.
In contrast to other polyQ diseases we examined, SCA3
does not fit our derived model (Figure 5), suggesting that
another factor, dependent on the repeat-length of polyQ
expansions, plays a critical role in determining disease
onset of SCA3. Recent studies have suggested that ataxin-
3 normally participates in protein quality control path-
ways in the cell [52,53]. Endoplasmic reticulum (ER)-
associated degradation (ERAD) is a quality control system
in the secretory pathway responsible for degrading mis-
folded proteins [54]. ERAD involves a series of steps to
extract proteins from the ER and deliver them to proteas-
omes. The key protein essential for extracting substrates
from the ER to the cytosol is valosin-containing protein
[55]. It is of interest that ataxin-3 binds valosin-containing
protein and regulates retrotranslocation of ERAD sub-
strates in a repeat-length-dependent manner [53]. These
findings underscore the critical role of protein quality
control in SCA3 pathogenesis and raise a possibility that
neuronal death in SCA3 exhibits sigmoidal kinetics.
Further study of disease progression as a function of CAG-
repeat length for each polyQ disease will be needed to
confirm the constancy of the slope and toxicity relation-
ships. These analyses will more precisely characterize rates
of disease progression whether it consists with exponen-
tial kinetics or sigmoidal kinetics.
One of the parameters, the slope of the regression curve,
clearly subdivided polyQ diseases into two groups. One
group included SCA1, -7 and HD; the other included
SCA2, -6 and DRPLA (Table 1). Accumulating evidence
Linear regression analysis of SCA3 Figure 5
Linear regression analysis of SCA3. A total of 308 SCA3 patients with expanded CAG repeats in the ataxin-3 gene was 
analyzed. Inspection of logarithmically transformed mean age-at-onset versus CAG size plots (A) identified 64, 82 and 83 CAG 
repeats as relative outliers. However, in contrast to the other polyQ diseases, natural log-transformed age-of-onset versus 
CAG size was the best fit to a negative quadratic function (B). Clearly, this indicates that the nucleated growth polymerization 
model is unsuitable for SCA3.
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strongly suggests that the cell nucleus is the main patho-
logical subcellular site for SCA1, -7 and HD [16-18],
whereas the cytoplasm is thought to be the site for SCA2
and SCA6 [19,20]. Clearly, the distribution into two
groups is consistent with the presumed main pathological
subcellular site in each disease. Further support for this
idea is provided by the observation that a smaller inter-
cept is consistently observed in the case of SCA1, -7 and
HD (Table 1). Given the nucleus-to-cytoplasm volume
ratio, it is expected that the concentration of degradation-
resistant mutant proteins would be higher in the nucleus
than in the cytoplasm. Another explanation for the
smaller intercept in SCA1, -7 and HD might be related to
the finding that the autophagy-lysosomal system is also
involved in cytoplasmic degradation of aggregate-prone
protein with polyQ, but the nucleus lacked this activity
[56].
The slope of in vitro aggregation of polyQ peptides is
0.1512 (Figure 1A), which is close to the slope for SCA2
(0.1217). In contrast to conventional models of nucleated
growth polymerization, the critical nucleus (the number
of monomeric unit comprising the nucleus) for polyQ
peptides aggregation is a monomer (n = 1) [9]. Assuming
that the cytoplasmic pathological sites are identical, com-
pared to the slope of SCA2, the slope of SCA6 (0.2567)
corresponds to a dimeric nucleus (n = 2). To date, there
are no data capable of providing a mechanism to explain
the aggregation of such a short polyQ expansion in SCA6.
Our model predicts that the aggregation in SCA6 is attrib-
utable to the dimeric nucleus, which promotes disease-
onset about 20 times more effectively than a monomeric
nucleus at a CAG size of 22. In contrast, the slopes of
SCA1, -7 and HD are substantially lower than the value of
0.1512 (Table 1), which corresponds to the smallest criti-
cal nucleus size. Therefore, a certain inhibitory factor such
as molecular chaperone or ubiquitin-proteasome system
is inferred to exist in the cell nucleus that reduces the
probability of nucleation to less than half the value of the
slope. This is compatible with the idea that nuclear inclu-
sion serves to protect against neurodegeneration in polyQ
diseases [57]. Taken together with the finding that SCA3
operates by a different mechanism, this suggests that
nuclear inclusion itself is an off-pathway product of nucle-
ated growth polymerization.
Based on the nucleated growth polymerization model, the
parameters derived from linear regression analysis have
led us to propose alternative therapeutic targets according
to the distinct subcellular loci (Figure 6). The slope (prob-
ability of nucleation at an individual repeat) and intercept
(inversely related to the concentration of soluble mutant
protein monomers) determines a critical number of the
nucleus, which initiates polymerization pathway, consid-
ered as a threshold of polyQ cytotoxicity. Our results sug-
gest that, in the cell nucleus, host defense factors
Alternative therapeutic targets according to distinct subcellular loci Figure 6
Alternative therapeutic targets according to distinct subcellular loci. The slope (probability of nucleation at an indi-
vidual repeat) and intercept (inversely related to the concentration of soluble mutant protein monomers) determines a critical 
number of the nucleus leading to polymerization pathway, considering as a threshold of polyQ cytotoxicity. Host defense fac-
tors (blue arrow) considerably inhibit the probability of nucleation in the cell nucleus. By contrast, the concentration of soluble 
mutant protein monomers in the cell nucleus is quite higher than the values in the cytoplasm. A rational therapeutic target (red 
arrow) is to reduce the concentration of soluble mutant protein monomers in the cell nucleus, and is to inhibit the probability 
of nucleation and reduce the concentration of soluble mutant protein monomers in the cytoplasm.
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considerably inhibit the probability of nucleation at an
individual mutant protein. By contrast, it is estimated that
the concentration of soluble mutant protein monomers in
the cell nucleus is quite higher than the values in the cyto-
plasm (e8.377~11.011 versus e6.249~6.657, the mean ratio is
about 40:1). Therefore, nuclear localization of the mutant
protein itself has great impact on the age-of-onset in
SCA1, -7 and HD. Theoretically, an attractive therapeutic
target is to reduce the concentration of soluble mutant
protein monomers in the cell nucleus, particularly by
inhibition of translocation of the mutant proteins from
the cytoplasm to the cell nucleus, and thereby delay
polyQ nucleation aggregation.
Conclusion
One of the striking findings of neurodegeneration
research is the observation that most of the proteins
implicated in disease have a strong propensity to aggre-
gate. Aggregation is a central aspect of the biology of many
neurodegenerative diseases. However, the role of aggre-
gates in neurodegeneration is unclear. In this article, we
present the first development of a mathematical model,
which describes the basis for genotype-phenotype correla-
tions in inherited neurodegenerative disorders known as
polyQ disease and have successfully established the com-
mon quantitative connection among polyQ diseases
between the repeat-length-dependent age-of-onset and
aggregation kinetics based on polyQ sequence. Our
results have clear implications for polyQ disease patho-
genesis and therapy.
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